ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0235

Mortality Trends due to Hypertension Related Deaths in Elderly Patients with Inflammatory Polyarthropathy: A CDC WONDER Analysis of 21 Years

ZAUHA FAWAD MEMON1, Sibgha Fawad Memon2, Matia Fawad Memon2, REHAN ISHAQUE3, AHMAD SANAN4 and MUHAMMAD MUGHEES5, 1Peoples University of Medical and Health Sciences for Women, Tando Allahyar, Sindh, Pakistan, 2Peoples University of Medical and Health Sciences for Women, Tando Allahyar, Pakistan, 3LIAQUAT UNIVERSITY OF MEDICAL AND HEALTH SCIENCES, Jam Shoro, Sindh, Pakistan, 4KHYBER MEDICAL COLLEGE, Peshawer, Pakistan, 5Bahria University health Sciences, KARACHI, Pakistan

Meeting: ACR Convergence 2025

Keywords: autoimmune diseases, Heart disease, Inflammation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0233–0279) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Inflammatory polyarthropathy (IPA) is a group of chronic autoimmune disorders, common among older adults and contribute significantly to systemic inflammation and cardiovascular risk . These conditions are associated with systemic inflammation, which leads to an elevated risk of cardiovascular diseases, notably hypertension (HTN). Recent studies suggest that people with IPA like rheumatic arthritis (RA) are 48% more likely to develop cardiovascular disorders than the general population. Emerging research underscores the role of immune-mediated inflammation in pathogenesis of HTN among patients with IPA. This study explores mortality rates due to IPA in patients with (HTN) patients aged 55 or above to inform prevention and care strategies.

Methods: We conducted a retrospective population-based study using the Centers for Disease Control and Prevention’s Wide-ranging Online Data for Epidemiologic Research system (CDC WONDER) death certificate data (1999-2020). Subjects with Inflammatory polyarthropathy and Hypertension (HTN) were selected. Age-adjusted mortality rates (AAMRs) per 100,000 were calculated, and trends were assessed using Joinpoint regression to estimate annual and average annual percent changes (APC, AAPC). Rates were stratified by year, gender, race/ethnicity, region, and urbanization.

Results: A total of 91,168 deaths were reported to be associated with Inflammatory polyarthropathy and hypertension between 1999-2020, of which males accounted for 35.68% and female accounted for 64.32%. The overall age-adjusted mortality rate (AAMR) increased from 3.01 in 1999 to 7.46 in 2020 (AAPC: 2.78, p < 0.050810). Females had a higher age-adjusted mortality rate than males (6.15 vs 5.17). Racial/ethnic disparities were apparent. Black or African American population had the highest AAMR (10.97 in 2020) (AAPC: 1.12, p < 0.565390). Asian or Pacific Islander had an overall similar trend (AAPC: -0.67, p < 0.170487). The trend in White people (AAPC: 2.90, p < 0.017643) remained almost consistent with sudden spike in 2020 (AAMR 7.18). Hispanic people had an overall upward trend (AAPC: 3.03, p < 0.013721).Geographically, all four U.S. Census regions showed statistically significant incline, most prominent in the Northeast (AAPC: 4.03) and South (AAPC: 2.75) regions.Both Urban and rural populations witnessed a substantial rise, however, it was more pronounced in rural population (AAPC: 3.30, p < 0.021351) as compared to urban (AAPC: 2.50, p < 0.083213)

Conclusion: Over the last 2 decades, mortality due to inflammatory polyarthropathy in patients with hypertension has remarkably increased. These findings highlight the need for targeted public health interventions and equitable access to address these disparities.

Supporting image 1Figure 1: showing an overall increase in mortality trend due to Inflammatory Polyarthropathy and Hypertension

Supporting image 2Figure 2: Showing disparities in mortality trends between sexes, with constant rise seen in males, and females demonstrating a biphasic pattern


Disclosures: Z. MEMON: None; S. Memon: None; M. Memon: None; R. ISHAQUE: None; A. SANAN: None; M. MUGHEES: None.

To cite this abstract in AMA style:

MEMON Z, Memon S, Memon M, ISHAQUE R, SANAN A, MUGHEES M. Mortality Trends due to Hypertension Related Deaths in Elderly Patients with Inflammatory Polyarthropathy: A CDC WONDER Analysis of 21 Years [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/mortality-trends-due-to-hypertension-related-deaths-in-elderly-patients-with-inflammatory-polyarthropathy-a-cdc-wonder-analysis-of-21-years/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mortality-trends-due-to-hypertension-related-deaths-in-elderly-patients-with-inflammatory-polyarthropathy-a-cdc-wonder-analysis-of-21-years/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology